期刊文献+

EZH2与乳腺癌分子亚型的关系及对临床病理的意义 被引量:2

Expression of EZH2 in breast cancer and its clinicopathological significance
下载PDF
导出
摘要 目的:研究EZH2与乳腺癌分子亚型和临床病理参数的关系,探讨EZH2对评价乳腺癌分子亚型预后的价值。方法:回顾分析80例临床病理资料及术后随访资料均完整的乳腺癌患者,通过免疫组织化学Max Vision快捷法,检测ER、PR、HER-2、CK5/6、CK14、EGFR、EZH2蛋白的表达,分析EZH2阳性表达与乳腺癌分子亚型及临床病理参数的关系,观察EZH2对患者预后的影响。结果:80例乳腺癌病例中,Luminal型49例,HER-2(+)型8例,Basal-like型20例,Normal breast-like型3例;各分子亚型只与患者绝经与否具有相关性;Luminal型乳腺癌总生存率最高,Basal-like型最低(P<0.05)。EZH2阳性表达率45.00%,其阳性表达与患者同侧腋窝淋巴结转移与否和肿瘤组织学分级及术后临床分期相关(P<0.05);EZH2在Luminal型、HER-2(+)型、Basal-like型乳腺癌阳性表达率分别为34.60%、50.00%和70.00%,差异有统计学意义(P<0.05)。结论:EZH2阳性表达提示患者预后不良;EZH2有望成为Basal-like型乳腺癌的特异性标记物之一。 Objective: To investigate the expression of EZH2 in breast cancer and its clinicopathologieal significance. Methods: Eighty cases of invasive breast cancer with complete clinlcpathological data and follow- up information were enrolled in the study. The expressions of ER, PR, HER-2, CK5/6, CK14, EGFR and EZH2 proteins were detected by immunohistochemistry (IHC). The relationship of EZH2 expression with molecular subtypes and prognosis of breast cancer was analyzed. Results: In 80 cases of breast cancer, there were 49 cases of Luminal subtype,8 cases of HER-2 ( + ) subtype ,20 cases of Basal-like subtype and 3 cases of Normal breast-like subtype. The molecular subtypes of breast cancer were associated with menopausal status of patients. Luminal subtype had the highest overall survival rate, while the Basal-like carcinomas were associated with the lowest survival ( P 〈 0. 05 ). The overall EZH2-positive expression rate was 45.00% and the expression was correlated with axillary lymph node metastasis, histological grading and clinical staging of breast cancer ( P 〈 0.05 ). The EZH2-positive expression rates in Luminal subtype, HER-2 ( + ) subtype and Basal-like subtype of breast cancers were 34.6% ,50.0% and 70.0% , respectively (P 〈 0.05 ). Conclusion: Positive expression of EZH2 may indicate a poor prognosis of breast cancer patients and it might be used as a novel therapeutic target for breast cancer of Basal-like subtype.
出处 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2013年第4期443-449,477,共8页 Journal of Zhejiang University(Medical Sciences)
关键词 乳腺肿瘤 病理学 乳腺肿瘤 病因学 基因 肿瘤 基因表达 免疫组织化学 乳腺癌 分子亚型 基底细胞样型 EZH2 Breast neoplasms/pathology Breast neoplasms/etiology Genes, neoplasm Geneexpression Immunohistochemistry Breast cancer Molecular subtype Basal-likesubtype EZH2
  • 相关文献

参考文献2

二级参考文献14

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:165
  • 2Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 4Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 5Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 6Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 7Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 8Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
  • 9Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.
  • 10Rhodes A, Jasani B, Anderson E, et al. Evaluation of HER-2/ neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol,2002,118 (3) :408-417.

共引文献207

同被引文献15

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部